- Home
- AMGN vs TTE Comparison
AMGN vs TTE Comparison
Compare AMGN & TTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- TTE
- Stock Information
- Founded
- AMGN 1980
- TTE 1924
- Country
- AMGN United States
- TTE France
- Employees
- AMGN N/A
- TTE N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- TTE Oil & Gas Production
- Sector
- AMGN Health Care
- TTE Energy
- Exchange
- AMGN Nasdaq
- TTE Nasdaq
- Market Cap
- AMGN 155.9B
- TTE 138.3B
- IPO Year
- AMGN N/A
- TTE 1991
- Fundamental
- Price
- AMGN $295.27
- TTE $63.03
- Analyst Decision
- AMGN Hold
- TTE Buy
- Analyst Count
- AMGN 20
- TTE 6
- Target Price
- AMGN $322.30
- TTE $69.96
- AVG Volume (30 Days)
- AMGN 2.7M
- TTE 1.7M
- Earning Date
- AMGN 08-05-2025
- TTE 07-24-2025
- Dividend Yield
- AMGN 3.22%
- TTE 4.15%
- EPS Growth
- AMGN 56.16
- TTE N/A
- EPS
- AMGN 10.94
- TTE 5.94
- Revenue
- AMGN $34,126,000,000.00
- TTE $191,626,000,000.00
- Revenue This Year
- AMGN $7.73
- TTE $0.91
- Revenue Next Year
- AMGN $1.68
- TTE $6.83
- P/E Ratio
- AMGN $27.00
- TTE $10.03
- Revenue Growth
- AMGN 15.56
- TTE N/A
- 52 Week Low
- AMGN $253.30
- TTE $52.78
- 52 Week High
- AMGN $346.85
- TTE $70.50
- Technical
- Relative Strength Index (RSI)
- AMGN 55.95
- TTE 57.23
- Support Level
- AMGN $291.25
- TTE $61.85
- Resistance Level
- AMGN $302.38
- TTE $62.80
- Average True Range (ATR)
- AMGN 8.76
- TTE 0.86
- MACD
- AMGN 1.17
- TTE 0.00
- Stochastic Oscillator
- AMGN 79.42
- TTE 85.39
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About TTE TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.5 million barrels of liquids and 5.2 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 11.1 billion barrels of oil equivalent, 54% of which are liquids. During 2024, it had LNG sales of 39.8 million metric tons. The company owns interests in refineries with a capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 26 gigawatts.